Cargando…
Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
BACKGROUND: The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been fully investigated. We compared the glucose-...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Endocrine Society
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803553/ https://www.ncbi.nlm.nih.gov/pubmed/26754588 http://dx.doi.org/10.3803/EnM.2016.31.1.161 |
_version_ | 1782422884158799872 |
---|---|
author | Bae, Jaehyun Lee, Min Jung Choe, Eun Yeong Jung, Chang Hee Wang, Hye Jin Kim, Myoung Soo Kim, Yu Seun Park, Joong-Yeol Kang, Eun Seok |
author_facet | Bae, Jaehyun Lee, Min Jung Choe, Eun Yeong Jung, Chang Hee Wang, Hye Jin Kim, Myoung Soo Kim, Yu Seun Park, Joong-Yeol Kang, Eun Seok |
author_sort | Bae, Jaehyun |
collection | PubMed |
description | BACKGROUND: The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been fully investigated. We compared the glucose-lowering efficacies of DPP 4 inhibitors and evaluate their effects on the blood levels of cyclosporine in renal transplant recipients with diabetes. METHODS: Sixty-five renal allograft recipients who received treatment with DPP-4 inhibitors (vildagliptin, sitagliptin, or linagliptin) following kidney transplant were enrolled. The glucose-lowering efficacies of the DPP-4 inhibitors were compared according to the changes in the hemoglobin A1c (HbA1c) levels after 3 months of treatment. Changes in the trough levels of the cyclosporine were also assessed 2 months after treatment with each DPP-4 inhibitor. RESULTS: HbA1c significantly decreased in the linagliptin group in comparison with other DPP-4 inhibitors (vildagliptin –0.38%±1.03%, sitagliptin –0.53%±0.95%, and linagliptin –1.40±1.34; P=0.016). Cyclosporine trough levels were significantly increased in the sitagliptin group compared with vildagliptin group (30.62±81.70 ng/mL vs. –24.22±53.54 ng/mL, P=0.036). Cyclosporine trough levels were minimally changed in patients with linagliptin. CONCLUSION: Linagliptin demonstrates superior glucose-lowering efficacy and minimal effect on cyclosporine trough levels in comparison with other DPP-4 inhibitors in kidney transplant patients with diabetes. |
format | Online Article Text |
id | pubmed-4803553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Korean Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-48035532016-03-27 Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study Bae, Jaehyun Lee, Min Jung Choe, Eun Yeong Jung, Chang Hee Wang, Hye Jin Kim, Myoung Soo Kim, Yu Seun Park, Joong-Yeol Kang, Eun Seok Endocrinol Metab (Seoul) Original Article BACKGROUND: The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been fully investigated. We compared the glucose-lowering efficacies of DPP 4 inhibitors and evaluate their effects on the blood levels of cyclosporine in renal transplant recipients with diabetes. METHODS: Sixty-five renal allograft recipients who received treatment with DPP-4 inhibitors (vildagliptin, sitagliptin, or linagliptin) following kidney transplant were enrolled. The glucose-lowering efficacies of the DPP-4 inhibitors were compared according to the changes in the hemoglobin A1c (HbA1c) levels after 3 months of treatment. Changes in the trough levels of the cyclosporine were also assessed 2 months after treatment with each DPP-4 inhibitor. RESULTS: HbA1c significantly decreased in the linagliptin group in comparison with other DPP-4 inhibitors (vildagliptin –0.38%±1.03%, sitagliptin –0.53%±0.95%, and linagliptin –1.40±1.34; P=0.016). Cyclosporine trough levels were significantly increased in the sitagliptin group compared with vildagliptin group (30.62±81.70 ng/mL vs. –24.22±53.54 ng/mL, P=0.036). Cyclosporine trough levels were minimally changed in patients with linagliptin. CONCLUSION: Linagliptin demonstrates superior glucose-lowering efficacy and minimal effect on cyclosporine trough levels in comparison with other DPP-4 inhibitors in kidney transplant patients with diabetes. Korean Endocrine Society 2016-03 2016-03-16 /pmc/articles/PMC4803553/ /pubmed/26754588 http://dx.doi.org/10.3803/EnM.2016.31.1.161 Text en Copyright © 2016 Korean Endocrine Society http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Bae, Jaehyun Lee, Min Jung Choe, Eun Yeong Jung, Chang Hee Wang, Hye Jin Kim, Myoung Soo Kim, Yu Seun Park, Joong-Yeol Kang, Eun Seok Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study |
title | Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study |
title_full | Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study |
title_fullStr | Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study |
title_full_unstemmed | Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study |
title_short | Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study |
title_sort | effects of dipeptidyl peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: a pilot study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803553/ https://www.ncbi.nlm.nih.gov/pubmed/26754588 http://dx.doi.org/10.3803/EnM.2016.31.1.161 |
work_keys_str_mv | AT baejaehyun effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy AT leeminjung effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy AT choeeunyeong effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy AT jungchanghee effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy AT wanghyejin effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy AT kimmyoungsoo effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy AT kimyuseun effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy AT parkjoongyeol effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy AT kangeunseok effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy |